Attached files
| file | filename |
|---|---|
| EX-32.1 - EX-32.1 - Strongbridge Biopharma plc | sbbp-20201231xex32d1.htm |
| EX-31.2 - EX-31.2 - Strongbridge Biopharma plc | sbbp-20201231xex31d2.htm |
| EX-31.1 - EX-31.1 - Strongbridge Biopharma plc | sbbp-20201231xex31d1.htm |
| EX-21.1 - EX-21.1 - Strongbridge Biopharma plc | sbbp-20201231xex21d1.htm |
| 10-K - 10-K - Strongbridge Biopharma plc | sbbp-20201231x10k.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements: (Form S-3 Nos. 333-223575 and 333-223576) of Strongbridge Biopharma plc, (Form S-8 No. 333-225319) pertaining to the 2017 Inducement Plan of Strongbridge Biopharma plc, (Form S-8 Nos. 333-222818 and 333-230931) pertaining to the 2015 Equity Compensation Plan, Non-Employee Director Equity Compensation Plan and 2017 Inducement Plan of Strongbridge Biopharma plc; (Form S-8 No. 333-215532) pertaining to the 2015 Equity Compensation Plan, Non-Employee Director Equity Compensation Plan and Individual Stock Option Agreements of Strongbridge Biopharma plc; and (Form S-8 No. 333-236911) pertaining to the 2015 Equity Compensation Plan and Non-Employee Director Equity Compensation Plan of Strongbridge Biopharma plc; of our report dated March 3, 2021, with respect to the consolidated financial statements of Strongbridge Biopharma plc included in this Annual Report (Form 10-K) for the year ended December 31, 2020.
/s/ Ernst & Young LLP
Philadelphia, Pennsylvania
March 3, 2021